Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director departure
Appointed director
Quarterly results
Consulting agrmnt
Employment agrmnt
Asset disposition
REPROS THERAPEUTICS INC. (RPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/21/2021 GN Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
04/21/2021 GN Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
04/15/2021 GN Royalty Pharma Declares Second-Quarter 2021 Dividend
04/08/2021 GN Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
02/17/2021 GN Royalty Pharma Reports Q4 2020 and Full-Year Results
01/22/2021 GN Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021
01/08/2021 GN Royalty Pharma Announces 13% Dividend Increase
12/22/2020 GN Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities
12/21/2020 GN Royalty Pharma Announces Expansion of Leadership Team
12/07/2020 GN Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals
12/07/2020 GN BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
11/10/2020 GN Royalty Pharma Reports Third Quarter 2020 Results
11/02/2020 GN Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
10/20/2020 GN Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
10/15/2020 GN Royalty Pharma Announces Pricing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
10/15/2020 GN Royalty Pharma Declares Fourth-Quarter 2020 Dividend
10/13/2020 GN Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
09/02/2020 GN Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes
08/25/2020 GN Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes
08/12/2020 GN Royalty Pharma Reports Second Quarter 2020 Results
08/07/2020 GN Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
08/03/2020 GN Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company's Board of Directors
07/20/2020 GN Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12
07/20/2020 GN Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
06/18/2020 GN Royalty Pharma Announces Closing of Initial Public Offering
01/26/2018 GN Repros Announces Negative Opinion From the EMA for Enclomiphene
01/04/2018 GN Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive Landscape
12/15/2017 GN Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
12/12/2017 GN Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
11/13/2017 GN Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
08/14/2017 GN Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results
07/17/2017 GN Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
05/18/2017 GN Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
05/17/2017 GN Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy